The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(S)-4-(4-((2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)piperazin-1-yl)-5-methoxythiazole ID: ALA5290877
Chembl Id: CHEMBL5290877
Max Phase: Preclinical
Molecular Formula: C17H21N3O3S
Molecular Weight: 347.44
Associated Items:
Names and Identifiers Canonical SMILES: COc1scnc1N1CCN(C[C@H]2COc3ccccc3O2)CC1
Standard InChI: InChI=1S/C17H21N3O3S/c1-21-17-16(18-12-24-17)20-8-6-19(7-9-20)10-13-11-22-14-4-2-3-5-15(14)23-13/h2-5,12-13H,6-11H2,1H3/t13-/m0/s1
Standard InChI Key: ORRUQJMDPIWMTK-ZDUSSCGKSA-N
Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 347.44Molecular Weight (Monoisotopic): 347.1304AlogP: 2.11#Rotatable Bonds: 4Polar Surface Area: 47.06Molecular Species: NEUTRALHBA: 7HBD: ┄#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): ┄#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 6.52CX LogP: 2.56CX LogD: 2.51Aromatic Rings: 2Heavy Atoms: 24QED Weighted: 0.84Np Likeness Score: -0.92
References 1. Wang S, Haikarainen A, Pohjakallio A, Sipilä J, Kaskinoro J, Juhila S, Jalava N, Koskinen M, Vesajoki M, Kumpulainen E, Pystynen J, Koskelainen T, Holm P, Din Belle D.. (2022) Development of benzodioxine-heteroarylpiperazines as highly potent and selective α2c antagonists., 77 [PMID:36174834 ] [10.1016/j.bmcl.2022.129005 ]